The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Targeting TGF-β signaling for the treatment of fibrosis
Abstract
Transforming growth factor-β (TGF-β) is widely recognized as a core pathway of fibrosis. Inhibition of TGF-β signaling may thus offer potential for antifibrotic therapies. Long-term inhibition of TGF-β signaling at the level of its isoforms and receptors can be associated with unacceptable adverse effects. However, TGF-β regulates a myriad of intracellular signaling cascades to transmit its profibrotic effects and several of those pathways offer potential for pharmacologic intervention. Moreover, the multiple interactions of TGF-β with other profibrotic pathways also yielded candidates for therapeutic intervention. In this review, we discuss selected targets within the TGF-β pathway with high translational potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Massagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,128
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,427
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Cited by
Signaling pathways and targeted therapy for myocardial infarction
Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00925-z · Cited by 831
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Self-citationTGF-β1 – A truly transforming growth factor in fibrosis and immunity
Lodyga, M., & Hinz, B. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.010 · Cited by 458
PU.1 controls fibroblast polarization and tissue fibrosis
Wohlfahrt, T., Rauber, S., Uebe, S., Luber, M., Soare, A., Ekici, A., Weber, S., Matei, A.-E., Chen, C.-W., Maier, C., et al. (2019) · Nature · doi:10.1038/s41586-019-0896-x · Cited by 187
Self-citationFarah, S., Doloff, J. C., Müller, P., Sadraei, A., Han, H. J., Olafson, K., Vyas, K., Tam, H. H., Hollister-Lock, J., Kowalski, P. S., et al. (2019) · Nature Materials · doi:10.1038/s41563-019-0377-5 · Cited by 181
Multipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease
Murphy-Ullrich, J. E. (2019) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155419851103 · Cited by 104
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis
Fang, D., Chen, B., Lescoat, A., Khanna, D., & Mu, R. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00864-7 · Cited by 84
Integrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74
Inhibition of NF-κB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis
Jaffar, J., Glaspole, I., Symons, K., & Westall, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111471 · Cited by 45
Chale-Dzul, J., Pérez-Cabeza de Vaca, R., Quintal-Novelo, C., Olivera-Castillo, L., & Moo-Puc, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.183 · Cited by 47
Inhibition of TGFβ1 activation prevents radiation-induced lung fibrosis
Yi, M., Yuan, Y., Ma, L., Li, L., Qin, W., Wu, B., Zheng, B., Liao, X., Hu, G., & Liu, B. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1546 · Cited by 33
Metadata
- Authors
- Györfi, A. H., Matei, A.-E., & Distler, J. H. W.
- Venue
- Matrix Biology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 68-69
- Pages
- 8-27
- ISSN
- 0945-053X (ISSN-L)
- OpenAlex
- W2794423958
- Cited by
- 274
- References
- 183
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.